PharmaMar Appoints Ali Zeaiter as New Director of Clinical Development
October 01, 2018 at 06:30 am EDT
Share
PharmaMar has announced the appointment of Dr. Ali Zeaiter, MD as the new Director of Clinical Development of the company, where he will be the director of the clinical development in the Oncology Business Unit. Ali Zeaiter is a medical oncologist with over 12 years experience in the pharmaceutical industry. Over 11 years at F. Hoffmann-La Roche Ltd., he was a member of the Life Cycle Team and core Project Team of different programs. In the last 7 years he worked as Global Clinical Leader and Global Development Team Leader on a number of projects, leading the Global Clinical Science and the Core Global Development Teams, and managing the teams' activities and deliverables.
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
PHARMA MAR, S.A. 
